arrow
H

Hélène Regnault

Henri Mondor Hospital
H指数:23
被引数:3,269

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical predictors of response to Atezolizumab-bevacizumab in Child-Pugh B patients with hepatocellular carcinoma

Child-Pugh B肝细胞癌患者对阿替利珠单抗-贝伐珠单抗反应的临床预测因子

2026-06-110
OAAI
Effectiveness and safety of selective internal radiation therapy using yttrium-90 glass microspheres for hepatocellular carcinoma: real-world results from the multi-center prospective PROACTIF cohort of 989 patients

钇-90玻璃微球选择性内部放疗治疗肝细胞癌的有效性与安全性:来自多中心前瞻性PROACTIF队列的989例真实世界结果

2026-04-170
OAAI
Clinical Impact of Extrahepatic Metastatic Patterns in Patients With Unresectable Hepatocellular Carcinoma Treated with Atezolizumab and Bevacizumab

不可切除肝细胞癌患者接受阿替利珠单抗和贝伐珠单抗治疗后,肝外转移模式的临床影响

2026-03-300
PRE
Feasibility and Effectiveness of Liver Transplantation following Immunotherapy in Patients with Hepatocellular Carcinoma

免疫疗法后肝移植在肝细胞癌患者中的可行性与有效性

2025-12-010
OA
The “A-B-C” classification reveals outcome trajectories in patients with hepatocellular carcinoma under atezolizumab/bevacizumab

“A-B-C”分类揭示了atezolizumab/bevacizumab治疗下肝细胞癌患者的结局轨迹

2025-11-250
OAAI
Response to systemic treatments and survival of fibrolamellar carcinomas: An AGEO-SFCE French multicenter retrospective cohort

对纤维层状癌的全身性治疗反应与生存:一项法国AGEO-SFCE多中心回顾性队列研究

2025-05-010
OAAI
Transjugular Intrahepatic Portosystemic Shunt (TIPS): A Bridge to Bariatric Surgery in Morbidly Obese Patients with Cirrhosis and Clinically Significant Portal Hypertension

经颈静脉肝内门体分流术(Transjugular Intrahepatic Portosystemic Shunt, TIPS):肥胖症患者(伴有肝硬化及临床显著门静脉高压)行减肥手术的桥梁

2024-12-290
PRE
Selective internal radiation therapy across Barcelona Clinic Liver Cancer (BCLC) stages of hepatocellular carcinoma: literature review

巴塞罗那临床肝癌 (BCLC) 肝细胞癌的选择性内部放射治疗: 文献综述

2024-12-011
OAAI
Patient and physician expectations regarding disease and treatment of advanced HCC: The prospective PERCEPTION1 study
2024-11-010
OAAI
Deep learning-based phenotyping reclassifies combined hepatocellular-cholangiocarcinoma
2023-12-1414
OAAI
Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area: What's new 12 months later?
2023-11-011
OAAI
Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO - PRODIGE 82)
2023-07-2910
OAAI
TACE and conformal radiotherapy vs. TACE alone for hepatocellular carcinoma: A randomised controlled trial
2023-04-013
OAAI